Clinical & demographic predictors of tuberculosis in children – A multi-centre prospective study in Low- and Middle-Income Countries

Franckling-Smith Z^{1*}, Olbrich L^{2, 3, 4*}, Larsson L², Sabi I⁵, Ntinginya NE⁵, Khosa C⁶, Banze D⁶, Nliwasa M⁷, Corbett EL^{7,8}, Semphere R⁷, Verghese VP⁹, Michael JS¹⁰, Razid A^{2, 3}, Graham SM¹¹, Song R⁴, Nabeta P¹², Trollip A¹², Hoelscher M^{2,4,13}, Geldmacher C^{2,4}, Zar HJ^{1°}, Heinrich N^{2, 4°} ¹Department of Paediatrics & Child Health, SA-MRC Unit on Child & Adolescent Health, University of Cape Town, South Africa; ²Division of Infectious Diseases and Tropical Medicine, University of Oxford, Oxford, UK; ⁴German Centre for Infection Research (DZIF), Partner Site Munich, Germany; ⁵National Institute for Medical Research Centre; ⁶Institute for Medical Research Centre; ⁶Instituto Nacional de Saúde (INS), Marracuene, Mozambique; ⁷TB/HIV Research Group, College of Medicine, Blantyre, Malawi; ⁸TB Centre, London School of Hygiene and Tropical Medicine, London, UK; ⁹Pediatric Infectious Diseases, Department of Paediatrics, Christian Medical College (CMC), Vellore, India; ¹⁰Department of Paediatrics, Christian Medical College (CMC), Vellore, India; ¹²FIND (Foundation for Innovative New Diagnostics), Geneva, Switzerland; ¹³Fraunhofer ITMP, Immunology, Infection and Pandemic Research, Munich, Germany

Objective

• To describe characteristics and determinants of TB disease in children in 5 high burden countries

Methods

- A prospective study of new diagnostics, of children (<15years) with suspected TB from 5 low-middle income countries • Baseline demographic, clinical and CXR data, and specimens for microbiological testing collected • Participants categorised as confirmed, unconfirmed or unlikely TB, by NIH consensus definitions • Logistic regression analyses were performed to identify co-variates associated with TB disease

Results

- 975 of 5,313 (18.4%) screened were enrolled
- Microbiological confirmation in 35.9% (239/665) with TB disease, 41.3% (38/92) in <1 year, 30.9% (102/330) <5 years, 25.5% (24/94) in CLHIV, and 48.1% (37/77) with severe acute malnutrition (SAM)

	All	Confirmed TB	Unconfirmed TB	Unlikely TB
	N = 975	n = 239 (24.5%)	n = 426 (43.7%)	n = 310 (31.8%)
Sex				
Female	470 (48.2)	115 (48.1)	203 (47.7)	152 (49.0)
Age				
Age in years, median (IQR)	4.9 (1.8 to 8.8)	6.2 (1.8 to 11.6)	4.6 (1.8 to 8.1)	4.7 (1.8 to 7.8)
Site				
South Africa	230 (23.6)	77 (32.2)	94 (22.1)	59 (19.0)
Tanzania	230 (23.6)	46 (19.2)	127 (29.8)	57 (18.4)
Mozambique	220 (22.6)	22 (9.2)	122 (28.6)	76 (24.5)
Malawi	201 (20.6)	34 (14.2)	74 (17.4)	93 (30.0)
India	94 (9.6)	60 (25.1)	9 (2.1)	25 (8.1)
HIV status ¹				
HIV infected	157 (16.1)	24 (10.0)	70 (16.4)	63 (20.3)
HIV-exposed uninfected	128 (13.1)	29 (12.1)	57 (13.4)	42 (13.5)
Nutrition ²				
Weight for age (z-score), mean (SD)	-1.2 (1.5)	-1.3 (1.5)	-1.1 (1.4)	-1.1 (1.5)
Severe acute malnutrition at baseline	111 (11.4)	37 (15.5)	40 (9.4)	34 (11.0)
Household exposures				
Exposure to indoor smoking	227 (23.4)	56 (23.5)	101 (23.9)	70 (22.7)
Immunological testing				
TST positive	413 (47.3)	131 (60.9)	264 (66.2)	18 (6.9)
CXR findings				
CXR findings attributable to TB	262 (26.9)	108 (45.2)	122 (28.6)	32 (10.3)
TB disease manifestation				
PTB only	376 (38.6)	139 (58.2	208 (48.8)	29 (9.4)
EPTB only	59 (6.1)	37 (15.5)	9 (2.1)	13 (4.2)
PTB & EPTB	99 (10.2)	57 (23.8)	34 (8.0)	8 (2.6)
TB treatment initiation				
Treatment for active TB, drug-sensitive	474 (48.6)	178 (74.5)	249 (58.5)	47 (15.2)
Treatment for active TB, drug-resistant	55 (5.6)	37 (15.5)	15 (3.5)	3 (1.0)
Preventive treatment	52 (5.3)	0 (0.0)	36 (8.5)	16 (5.2)

Data are n (%), except where noted otherwise. IQR: Interquartile range, SD: Standard deviation, TST: Tuberculin skin test, CXR: chest X-ray, PTB: Pulmonary TB, EPTB: Extrapulmonary TB.¹ HIV status not available for 25 participants; ² Nutritional status assigned according to WHO 2006 child growth standards.











Table 2: Multivariable logistic regression of demographic and clinical characteristics with confirmed PTB

Confirmed PTB vs Unlikely PTB										
Covariate	n	n-pos.	%-pos.	aOR	95% CI	p-value				
Site										
South Africa*	74	43	58,1	1		-				
Tanzania	93	41	44,1	2,76	(0.74 to 10.29)	0.1293				
Mozambique	32	7	21,9	0,99	(0.17 to 5.72)	0.9878				
Malawi	106	27	25,5	1,53	(0.43 to 5.39)	0.5094				
ndia	42	28	66,7	5,47	(1.35 to 22.14)	0.0172				
Sex										
Male	173	72	41,6	1,71	(0.85 to 3.46)	0.1340				
HIV status										
HIV infected	54	14	25,9	0,89	(0.32 to 2.46)	0.8267				
TST Result										
Positive	108	96	88,9	45,16	(18.43 to 110.66)	0.0000				
BCG received										
Yes	332	133	40,1	0,14	(0.02 to 1.35)	0.0893				
Severe acute malnutrition	at baseline ¹									
Yes	44	21	47,7	0,71	(0.24 to 2.12)	0.5428				
Number of TB symptoms										
1-2	96	31	32,3	0,94	(0.14 to 6.15)	0.9506				
2-4	173	67	38,7	1,49	(0.19 to 11.63)	0.7051				
>4	63	39	61,9	4,23	(0.36 to 49.23)	0.2492				
Chest radiograph findings										
Abnormal – Likely TB	94	75	79,8	7,98	(3.04 to 20.92)	0.0000				
Abnormal – Equivocal	89	32	36	1,18	(0.50 to 2.79)	0.7047				

- p<0.0001)
- 8.05[2.41-26.94], p=0.0007)
- 12.63[2.511-63.54], p=0.0021)
- 7.26[2.88-18.27], p<0.0001)

Conclusions











• PTB disease associated with a positive TST (aOR: 68.48 [33.23-141.10], p<0.0001) or CXR likely TB (aOR: 9.12 [4.75-17.5],

• For CLHIV, confirmed PTB and PTB disease associated with CXR likely TB (aOR: 23.11[1.33-401.43], p=0.0311 and aOR:

• For **SAM**, confirmed PTB and PTB disease associated with CXR likely TB (aOR: 34.72[2.73-441.94], p=0.0063 and aOR:

• In <2 years, confirmed PTB associated with a positive TST (aOR: 15.32[5.45-43.08], p<0.0001) and, CXR likely TB (aOR:

• One of the largest childhood cohorts, across 5 countries

Over half with TB disease diagnosed based on clinical and radiological features

• High rates of microbiological confirmation

• Clinical determinants differ among vulnerable subgroups, highlighting need for adapted diagnostic approaches



Acknowledgments: The authors thank all study participants, participating sites, and project team members for their contributions to the success of this project.